program

the **extracellular matrix** pharmacology congress

the 2nd extracellular matrix pharmacology congress 2024

17-19 JUNE 2024
COPENHAGEN
DENMARK

the **extracellular matrix** pharmacology congress

Index


DSB
Train tickets

Organisation

Scientific Committee

Alexandra Møller
Denmark

Ali Mobasheri
Finland

Adam Croft
United Kingdom

Aleksander Krag
Denmark

Alexander Nyström
Germany

Andrea Heinz
Denmark

Dana Orange
USA

Detlef Schuppan
Germany

Dinesh Khanna
USA

Eric White
USA

Faiez Zannad
France

Florian Rieder
USA

Gisli Jenkins
United Kingdom

Janine Erler
Denmark

Judith Ertle
Germany

Michael Cooreman
USA

Morten Karsdal
Denmark

Oliver Distler
Switzerland

Rachel Chambers
United Kingdom

Raghu Kalluri
USA

Saurabh Gupta
USA

Scott Friedman
USA

Sylvie Ricard-Blum
France

Thomas Cox
Australia


NYHAVN 17
NYHAVN 17
FREDSFONDENS HUS
CAP HORN
SKAGEN

Welcome

Dear Colleagues and Friends,

I am privileged to welcome you to the 2nd Extracellular Matrix Pharmacology Congress (ECM2024) on June 17-19, 2024, in beautiful Copenhagen, Denmark.

Dysregulation of the ECM, characterized by either elevated degradation or formation of tissues, is a universal characteristic observed in many chronic diseases. To make a real impact on the lives of patients, we need to learn from other diseases where fibrosis and tissue destruction are central mechanisms involved in pathophysiology.

After numerous years of ECM research, it became clear to me that we need a forum to bring leading experts across borders and generations together to discuss how to modulate the ECM in different disease areas. Thus, the idea for the ECM Pharmacology Congress was born.

ECM2022 was a great success with more than 400 participants from 30 countries, 200 high-quality abstracts, and 40 speakers – all with one goal: improving our understanding of the ECM across different diseases. Moreover, ECM2022 gave rise to a series of virtual symposiums which further advances our understanding of these critical subjects.

At ECM2024, we aim to repeat the success and offer an unforgettable mix of networking and state-of-the-art research. The program will include internationally renowned ECM researchers and industry experts from different disease areas: liver, lung, kidney, cardiovascular, metabolic, cancer (tumor fibrosis), skin, and immunology, in which the central common denominator is changes to the ECM.

The Congress is supported by the pharmaceutical industry and other companies, who, however, do not have influence on the scientific program.

The central theme of ECM2024 will revolve around target discovery and drug development, intending to cross-fertilize and assist drug development. The center of it all will be ECM pharmacology and how its modulation can help patients.

I hope you will enjoy ECM2024 and your stay in Copenhagen!

Morten Karsdal
PhD, Professor
Chair ECM2024

General Information

Congress Website
www.ecm-congress.org

Congress Venue
Tivoli Hotel & Congress Center
Arni Magnussons Gade 2
DK-1577 Copenhagen

Hosted by

The International Society of Extracellular Matrix Pharmacology
Vesterlundvej 20
DK-2730 Herlev
info@isecmp.org

Congress Secretariat
CAP Partner
Nordre Fasanvej 113, 1
DK-2000 Frederiksberg
Tel.: +45 70 20 03 05
info@cap-partner.eu
www.cap-partner.eu

Badges
Congress name badges must be worn during the congress. Access to the congress venue will not be granted without a name badge issued by the congress secretariat.

Information for Speakers
Please bring your presentation on a USB stick to the Speakers Preview Room at the venue. A technician will assist you in uploading the presentation. Please ensure that you upload your presentation at least 2 hours before your session starts. The format of presentations should be 16:9 in Microsoft PowerPoint.
Personal laptops cannot be used for presentations.
At the end of the congress, all presentations will be deleted to prevent any copyright issues from arising.

Speakers Preview Room
Opening hours:

Monday, 17 June	08:00 - 17:00
Tuesday, 18 June	08:00 - 17:00
Wednesday, 19 June	08:00 - 13:30

WIFI
Free WIFI access is provided at the congress venue. Network Name:

Tivoli Hotel & Congress Center
Password: tivolihotel

Social Events

Welcome Reception

Date 17 June 2024
Time 18:00 - 19.00
Place Exhibition Area

The reception is included in the registration fee.



Run

Date 18 June 2024
Time 07.00 - 07:45
Place Meeting point:
Registration desk at congress venue

Join the 5 km run in the Copenhagen harbor area. Shower facilities are available at the congress venue.

Congress Dinner

Date 18 June 2024
Time 19.00 - 24.00
Place Skuespilhuset (Royal Danish Playhouse)

Boat trip from the congress venue to the dinner venue 18:15-18:40
Sightseeing boats will depart from the harbour just across from the congress venue 18:15-18:40 (the first boat with 100 seats leaves at 18:15 – the next boats will leave 10 minutes later)

This is a ticketed event. The dinner ticket is not included in the registration fee.



Program Monday, 17 June 2024

Time	Congress Hall
08:00 - 09:00	**Welcome and registration** Poster Hanging and Danish Pastry
08:45 - 09:00	**Coffee break and exhibition**
09:00 - 10:15	**Opening session**
09:00 - 09:30	**Morten Karsdal** Welcome and introduction.
09:30 - 10:15	**K1 Raghu Kalluri** The function of fibroblasts and collagen on organ fibrosis and cancer.
10:15 - 10:45	**Coffee break and exhibition**
10:45 - 12:20	**Plenary session** **The Essential Components of the ECM**
10:45 - 11:10	**Scott Friedman** Insights into the cell biology of fibrosis and prospects for new targets.
11:10 - 11:35	**Sylvie Ricard-Blum** The ECM crosslinking enzyme lysyl oxidase: a structurally and functionally challenging therapeutic target.
11:35 - 11:50	**OP1 Jaimes Campos** Common molecular (omics) fibrotic signature across organs affected by fibrosis in chronic diseases.
11:50 - 12:05	**OP2 Jade Celis** Identifying genetic markers of fibrostenosis in patients with Crohn's disease.
12:05 - 12:20	**OP3 Sarah Palko** Determining the effects of VEGF/Ang2 inhibition on collagen dynamics and deposition in the 2-hit model of subretinal fibrosis.
12:20 - 13:45	**Lunch and exhibition**

Time	Harlekin
08:15 - 08:45	**Meet the Experts** Everything You Want to Know About ECM
12:50 - 14:00	**Industry-sponsored symposium** **Targeting Fibrosis: Changing the ECM I**
12:50 - 13:10	**Michael Cooreman, Inventiva** PPARs: regulators of tissue remodeling.
13:10 - 13:25	**Chris Stevenson, Engitix Therapeutics** Beyond the cells: decoding the extracellular matrix to develop novel therapies for fibrosis and cancer.
13:25 - 13:40	**Paul Yaworsky, Mediar Therapeutics** Anti-WISP1 (MTX-463) as a novel potential therapy for idiopathic pulmonary fibrosis.
13:40 - 13:55	**Lara Perryman, Syntara** Finally an anti-fibrotic! Clinical efficacy of lysyl oxidase inhibitors.
13:55 - 14:00	**Q&A**

Monday, 17 June 2024

Columbine		Pjerrot
12:50-13:55	**Industry-sponsored symposium** **ECM Remodeling in Obesity and Metabolic Disorders: Causing Heart Failure**	
12:50-13:20	**Mads Røpke, Novo Nordisk** Modulation of the extracellular matrix in Cardiometabolic Disease.	
13:20-13:35	**Zvonko Milicevic, Eli Lilly** Effects of tirzepatide and retatrutide in the liver: results of the phase 2 trials.	
13:35-13:50	**Joel Mathews, Ionis Pharmaceuticals** The formation of TTR fibrils and fibrosis.	
13:50 - 13:55	**Q&A**	

Program Monday, 17 June 2024

	Congress Hall
14:00 - 15:35	**Plenary session** **The Importance of ECM in Cancer**
14:00 - 14:25	**Thomas Cox** Deconstructing cancer ecosystems: the matrix perspective.
14:25 - 14:40	**Saurabh Gupta** Pathological, prognostic and predictive role of circulating extracellular matrix markers in solid tumors.
14:40 - 15:05	**Janine Erler** ECM regulation of metastatic growth.
15:05 - 15:20	**OP4 Marina Pajic** Reprogramming of pro-fibrotic immuno-suppressive pancreatic cancer environment by anti-fungal itraconazole enhances the overall anti-tumor response.
15:20 - 15:35	**OP5 Nicholas Willumsen** Type III collagen pro-peptides in serum (PRO-C3) as a prognostic biomarker of survival in clinical cancer trials with a FDA letter-of-support.
15:35 - 15:50	**Coffee Break and Exhibition**
17:00 - 18:00	**Poster session 1** **(P027-P048, P077-P108)** **Categories:** Cancer and Tumour Microenvironment, Cardiometabolic Diseases, Liver and Lung Diseases, Matrix Biology.
18:00 - 19:00	**Welcome Reception**

	Harlekin
15:50 - 16:45	**Industry-sponsored symposium** **Quantifying Fibrosis**
15:50-16:05	**Louis Petitjean, PharmaNest** Digital pathology and artificial intelligence quantification of fibrosis and inflammation.
16:05-16:20	**Lars Johansson, Antaros Medical** Non-invasive imaging of fibrogenesis and fibrosis.
16:20-16:35	**Aidan MacNamara, Bayer** FIGARO-BM, a biomarker study of FIGARO-DKD, reveals new insights into the mode-of-action of finerenone
16:35-16:45	**Q&A**
17:15 - 18:00	**Panel discussion** **Drug Development in Fibrosis: Challenges and Opportunities** **Panel:** Michael Cooreman, Saurabh Gupta and Paul Yaworsky.

Columbine		Pjerrot
15:50-16:55	**Industry-sponsored symposium** Unraveling ECM Dynamics: Techniques	
15:50-16:05	**Evelyn Aranda, Xylyx Bio** IN MATRICO: a 3D assay platform based on human tissue-specific dECM for the study of cancer and fibrosis.	
16:05-16:20	**Luca Bersanini, Optics11 Life** Unravel the role of ECM in fibrosis.	
16:20-16:35	**Hamid Khoja, FibroBiologics** Potential use of fibroblast spheroids for the treatment of chronic wounds and psoriasis.	
16:35-16:50	**Molly Coseno, Sengenics** Autoantibody profiling: unique insights into ECM relevant diseases.	
16:50 - 16:55	Q&A	

Program Tuesday, 18 June 2024

	Congress Hall
09:00 - 10:25	**Plenary session** **Dermatology and the ECM**
09:00 - 09:25	**Alexander Nyström** What a genetic disease of the matrix can tell us about inflammation-driven fibrosis.
09:25 - 09:40	**Simon Francis Thomsen** Hidradenitis suppurativa and ECM.
09:40 - 09:55	**OP6 Dana Woerz** Extracellular matrix remodeling in atopic dermatitis.
09:55 - 10:10	**OP7 Hannah Paish** Development of an ex-vivo full-thickness skin model for drug testing and disease modelling.
10:10 - 10:25	**OP8 Alexander Eckersley** Novel proteomic approaches for identifying organ-conserved extracellular matrix damage in ageing.
10:25 - 11:00	**Coffee Break and Exhibition**

	Harlekin
08:00 - 08:50	**Industry-sponsored symposium** **Elastin and Collagens in Health, Aging and Disease**
08:00 - 08:30	**Hervé Pageon, L'Oréal** Aging of human skin, focus on the glycation reaction, its modeling and its effects on reconstructed skin.
08:30 - 08:45	**Andrea Heinz, University of Copenhagen** Aging of elastic fibers in the skin and cardiovascular system.
08:45- 08:50	**Q&A**

Columbine		Pjerrot
08:00 - 09:05	**Industry-sponsored symposium** Exploring Anti-Inflammatory and Anti-Fibrotic Drugs: Model Systems	
08:00 - 08:15	**Benjamin Simona, Ectica Technologies** 3DPROFIB: innovative in vitro system for ECM remodeling and evaluation of antifibrotic compounds.	
08:15 - 08:30	**Henrik Björk Hansen, Gubra** Distinct and shared therapeutic effects of semaglutide in preclinical models of fibrotic diseases.	
08:30 - 09:00	**Vince Fiore, Boehringer Ingelheim** Modeling fibroblast heterogeneity in vitro for drug discovery.	
09:00 - 09:05	**Q&A**	

Program Tuesday, 18 June 2024

	Congress Hall
12:00 - 13:45	**Lunch and Exhibition**

Harlekin	
11:00 - 12:00	**Rapid Oral Session 1**
11:00 - 11:10	**RP1 Lena Willmer** The efficacy of pharmacological interventions on ECM genes and proteins in human lung tissue and a microphysiological system for enhanced cultivation.
11:10 - 11:20	**RP2 Adam Bøgh Marstrand-Jørgensen** Mapping progression of DKD in ReninAAV UNx db/db mice utilizing time-series RNA sequencing.
11:20 - 11:30	**RP3 Hannah Tompkins** High-dimensional imaging analysis reveals distinct immuno-matrix signatures across human lung diseases.
11:30 - 11:40	**RP4 Fabio Bignami** The clinically relevant PRO-C3 biomarker: a new string to the bow of bleomycin model of pulmonary fibrosis.
11:40 - 11:50	**RP5 Paola Occhetta** Pathological hallmarks of human cardiac fibrosis in a mechanically active organ-on-chip to predict the efficacy of drugs and advanced therapies.
11:50 - 12:00	**RP6 Nicole Stupka** ADAMTS-5 inhibition by GLPG1972 reduces muscle inflammation and fibrosis and improves contractile function in muscular dystrophy.
12:30 - 13:30	**Industry-sponsored symposium** **Organ Fibrosis: Key Differences and Common Denominators**
12:30 - 12:45	**Federica Genovese, Nordic Bioscience:** Kidney/Heart
12:45 - 13:00	**Diana Julie Leeming, Nordic Bioscience:** Liver/Lung
13:00 - 13:15	**Joachim Høg Mortensen, Nordic Bioscience:** Gut
13:15 - 13:30	**Q&A and Panel Discussion**

Columbine	
11:00 - 12:00	**Rapid Oral Session 2**
11:00 - 11:10	**RP7 Matej Andelic** A novel biomarker of type VII collagen degradation is increased in patients with atopic dermatitis and lowered with immunosuppressant treatment.
11:10 - 11:20	**RP8 Marcos Burger Ramos** Engineering ECM-degrading bacteria to boost anti-cancer immunity in immune-excluded solid cancers.
11:20 - 11:30	**RP9 Andre Broermann** Non-invasive assessment of hepatic fibrosis in preclinical rodent model.
11:30 - 11:40	**RP10 Si Yuen Lee** Development of glioblastoma micro-environment using 3D printed polysaccharide bioinks for an in-vitro tumour model.
11:40 - 11:50	**RP11 Ellen Bamberg** Obesity-driven changes in breast extracellular matrix exhibit a pro-angiogenic phenotype.
11:50 - 12:00	**RP12 Giusy Di Conza** Autotaxin targeting in metastatic PDAC: preclinical and preliminary clinical data.
12:30-13:35	**Industry-sponsored symposium** **Targeting Fibrosis: Changing the ECM II**
12:30 - 12:45	**Kjetil Ask, Novartis** Multiomics towards precision medicine for fibrosis.
12:45 - 13:00	**Håkan Wennbo, Takeda**
13:00 - 13:15	**Mahru An, Pliant Therapeutics** Bexotegrast attenuates expression of core matrisome components in human fibrotic PCLS.
13:15 - 13:30	**Jannie Sand, Nordic Bioscience** Exploring the relationship between type VI collagen degradation and severe acute exacerbations of chronic obstructive pulmonary disease: findings from the ECLIPSE study.
13:30 - 13:35	**Q&A**

Pjerrot	
11:00 - 12:00	**Rapid Oral Session 3**
11:00 - 11:10	**RP13 Thomai Tsapanou-Katranara** Immune-cell specific biomarker of early intestinal inflammation: HNE degraded fragment of type III collagen is elevated in patients with IBD.
11:10 - 11:20	**RP14 Ling Wu** The improvement of bortezomib on cirrhosis and its potential mechanism.
11:20 - 11:30	**RP15 Jie Li** The extracellular matrix (ECM) turnover profile in eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis (EGE) – an exploratory study.
11:30 - 11:40	**RP16 Aurélie Moniot** Intersecting the TSP-1/CD47 axis: a promising strategy for treating ovarian cancer.
11:40 - 11:50	**RP17 Michael Hühn** Arrested development: Spatial exploration of divergent paths of alveolar regeneration in the bleomycin mouse model versus human lung fibrosis.
11:50 - 12:00	**RP18 Christophe Roubeix** Neovascular Age-related Macular Degeneration (nAMD)-associated fibrosis characterization and in vitro modelization.

Program Tuesday, 18 June 2024

	Congress Hall	Harlekin
13:45 - 15:30	**Plenary session** **Tissue Destruction in Inflammatory Diseases**	
13:45 - 14:10	**Florian Rieder** Mechanisms of intestinal repair and fibrosis.	
14:10 - 14:25	**OP9 Kirsty Houslay** RXC008, a highly potent GI-targeted pan-ROCK inhibitor, is a first-in-class approach to treat fibrostenotic Crohn's disease.	
14:25 - 14:40	**OP10 Marta Alexdóttir** CPa9-HNE: a neutrophil-derived fragment of calprotectin measured in serum can monitor endoscopic and clinical disease activity in ulcerative colitis.	
14:40 - 15:30	**Panel Discussion:** **Tissue Destruction in Systemic Sclerosis with Oliver Distler and Dinesh Khanna** How disease pathogenesis influences proof of concept clinical trial design.	
15:30 - 15:45	**Coffee Break and Exhibition**	
15:45 - 16:45	**Poster session 2** **(P001-P026, P049-P076, P109-P127)** **Categories**: Biomarkers, ECM Pharmacology, Models of Fibrosis and Inflammation.	
17:00 - 17:45	**Keynote**	
	K2 Gisli Jenkins The molecular pathology of idiopathic pulmonary fibrosis.	
19:00 - 24:00	**Congress Dinner**	

Columbine	Pjerrot

Program Wednesday, 19 June 2024

	Congress Hall
08:45 - 09:15	**Coffee Break and Exhibition**
09:15 - 10:50	**Plenary session** **Treating the ECM in Lung Diseases**
09:15 - 09:40	**Martin Decaris** Application of molecular imaging, transcriptomics and biomarkers in the development of bexotegrast.
09:40 - 10:05	**Rachel Chambers** Cell signalling and reconfiguration of metabolic networks during fibrogenesis.
10:05 - 10:20	**OP11 Katy Roach** Proteomic evaluation of a human lung model of fibrosis for novel therapeutic target selection.
10:20 - 10:35	**OP12 Iain Stewart** Genetic burden of extracellular matrix components in pulmonary fibrosis.
10:35 - 10:50	**OP13 Paul Yaworsky**
10:50 - 11:00	**Coffee Break and Exhibition**

	Harlekin
08:00-08:50	**Industry-sponsored symposium** **The Fibro-Inflammatory Axis: Fibroblasts and Tissue Destruction**
08:00 - 08:15	**Dana Orange, Rockefeller University** The role of fibroblasts in rheumatoid arthritis flare and pain.
08:15 - 08:30	**Adam Croft, University of Birmingham**
08:30 - 08:45	**Anne-Christine Bay-Jensen, Nordic Bioscience** Quantifying the fibrotic component in rheumatic diseases.
08:45-08:50	**Q&A**

Wednesday, 19 June 2024

Columbine	
08:00 - 09:10	**Industry-sponsored symposium** **Where Science Meets Business: The Transformative Role of Proteomics in Advancing Precision Medicine**
08:00 - 08:10	**Ruedi Stoffel, Roche** Increasing the odds in biomarker development.
08:10 - 08:25	**Veronica Miller, University of California, Berkeley** Stable consortia for driving innovation in the public-private interaction.
08:25 - 08:40	**Darcey Black, TherapeutAix** Drug discovery and development in IPF: how can biomarkers support making key decisions?
08:40 - 08:55	**Graham Clarke, AstraZeneca** Extracellular matrix biomarker development in respiratory & Immunology: An opportunity for precision medicine.
08:55 - 09:10	**Q&A and Panel Discussion**

Pjerrot	
08:15 - 08:45	**Meet the Experts** **The Best ECM Papers Published**

Program Wednesday, 19 June 2024

	Congress Hall	Harlekin
11:00-12:45	**Plenary session** **ECM Remodeling in Liver and Heart Diseases**	
11:00 - 11:25	**Aleksander Krag** ECM and the liver: ready for clinical translation?	
11:25 - 11:50	**Judith Ertle** Assessment of fibrosis in the liver – MASH and beyond.	
11:50 - 12:15	**Faiez Zannad** Clinical characterization of ECM related mechanisms in cardiovascular disease and therapy.	
12:15 - 12:30	**OP14 Erik Tillman** EFX improved biomarkers of fibrogenesis-to-fibrolysis balance consistent with a shift to beneficial ECM remodeling in patients with F2-F3 MASH.	
12:30 - 12:45	**OP15 Clara Laursen** Increased collagen type VI formation is associated with the risk of experiencing major adverse cardiovascular events in individuals with type 2 diabetes.	
12:45 - 13:15	**Light lunch and Exhibition**	
13:15-14:30	**Closing Session** **Keynote, Congress Summary and Abstract Awards**	
13:15 - 14:00	**K3 Detlef Schuppan** Translational approaches (ECM-related) to reverse liver fibrosis and liver cancer.	
14:00 - 14:30	**Congress Summary and Abstract Awards**	

Columbine	Pjerrot

Poster Overview

Poster	Abstract Title	Presenter Name	Country
P001	Capture the skin aging condition using specific biomarkers of extracellular matrix turnover	Pageon, Hervé	France
P002	Exploring Extracellular Matrix Markers in Ulcerative Colitis: Degradation and Formation Insights	Poulsen, Anja	Denmark
P003	Serum levels of anastellin (FN-ANA) are increased in IPF and associated with forced vital capacity and treatment status	Hansen, Annika Hummersgaard	Denmark
P004	Novel matricellular serum fibrosis marker thrombospondin-2 predicts liver fibrosis and fibrogenesis in patients with primary sclerosing cholangitis	Surabattula, Rambabu	Germany
P005	Serum type XII collagen is elevated in patients with solid tumors and is upregulated in CAFs and NFs upon TGFb treatment	Crespo-Bravo, Marina	Denmark
P006	Canstatin, a type IV collagen fragment, is associated with risk of cardiovascular and all-cause mortality in patients with advanced atherosclerosis	Angeli, Elisavet	Denmark
P007	Serum thrombospondin 2 and IGFBP-7 predict advanced liver fibrosis in patients with common variable immunodeficiency	Myneni, Sudha Rani	Germany
P008	Biomarkers of active fibrogenesis and immune cell activity are prognostic for liver-related outcomes in patients with hepatitis C in the HALT-C trial	Skovgaard, Emilie	Denmark
P009	Biomarkers of collagen synthesis as risk markers for pulmonary fibrotic scarring following Covid-19 Infection	Nielsen, Anne Orholm	Denmark
P010	Biomarkers quantifying changes in the hair follicular extracellular matrix are elevated in patients with alopecia	Port, Helena	Denmark
P011	C1M, a collagen type-I degradation biomarker is associated to increased risk of mortality in patients admitted with ST-elevated myocardial infarction	Martin, Emily	Denmark
P012	Serological type VIII collagen turnover (PRO-C8) is a potential prognostic and pharmacodynamic biomarker for idiopathic pulmonary fibrosis	B. Simões, Filipa	Denmark
P013	Variations in fibrotic activity of cancer-associated fibroblasts from different tissues measured using non-invasive, clinically validated biomarkers	Hettich, Annika	Denmark
P014	Fibroblast activity kills - Serum endotrophin (PRO-C6) is prognostic for liver-related events in patients with cirrhosis from chronic hepatitis C	Berg, Thomas	Denmark
P015	Biomarker Evaluation in Suspected Periprosthetic Joint Infections Following Hip and Knee Arthroplasty	Thudium, Christian S.	Denmark

P016	Detection of oncofetal chondroitin sulfate proteoglycans in plasma as diagnostic signatures for colorectal cancer	Agerbæk, Mette Ørskov	Denmark
P017	Serological biomarkers of extracellular matrix remodeling are elevated in patients with immune-mediated alopecia	Sinkeviciute, Dovile	Denmark
P018	PRO-C22 - a novel serological biomarker of tissue damage is associated with disease severity, disease activity, and systemic inflammation in patients with hidradenitis suppurativa	Holm Nielsen, Signe	Denmark
P019	A novel serological biomarker of type VI collagen turnover is increased in patients with atopic dermatitis and lowered when receiving immunosuppressant treatment	Møller Hausgaard, Cecilie	Denmark
P020	PRO-C11 and PRO-C16 are markers of intestinal fibrosis and are associated with mre-confirmed intestinal strictures – results from the imagekids study	Mortensen, Joachim Høg	Denmark
P021	Blood-based biomarkers of neutrophil and macrophage activity are elevated in serum from patients with dermatological conditions	Holm Nielsen, Signe	Denmark
P022	The activity of fibroblast activation protein (FAP) is reflected by a specific fragment of type III collagen that can be serologically assessed and serve as a non-invasive biomarker	Pedersen, Rasmus Sund	Denmark
P023	Improved understanding of the fibro-inflammatory relation in alcohol-related liver disease using serological markers may aid in the understanding of the gut-liver axis	de Zawadzki, Andressa	Denmark
P024	The non-invasive fibrosis biomarker PRO-C3 is elevated in patients with myeloproliferative neoplasms and associate with disease severity and JAK2V617F allele burden	Bistrup, Caroline Norup	Denmark
P025	A fragment of isomerized type III collagen is a potential risk marker for chronic kidney disease progression in individuals with type 2 diabetes and microalbuminuria	Chrysoulidou, Theodora	Denmark
P026	Elevated turnover of type VII collagen anchoring fibril in inflammatory bowel disease	He, Yi	Denmark
P027	TIMP-1 is a major driver of the angiogenic priming of tumor-associated fibroblasts in lung adenocarcinoma	Díaz-Valdivia, Natalia	Spain
P028	Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of the antifibrotic drug nintedanib in lung adenocarcinoma	Alcaraz, Jordi	Spain
P029	Matrix Morphology Matters: Implications for Assessing Lymph Node Metastasis Risk in Early-Stage Colon Cancer	Ravensbergen, Cor	Netherlands
P030	Advanced 3D-tool to improve therapeutic strategies for METex14 mutated lung cancers	Fernandes, Marie	France
P031	Bioinformatic analysis of protemic datasets reveals extracellular matrix proteins involved in metatastatic spread of uveal melanoma	Hattersley, Joshua	United Kingdom

P032	A pro-invasive mechanical cross-talk between cancer cells and cancer-associated fibroblasts	Mohammadi, Hamid	United Kingdom
P033	Universal" fibroblast-specific expression of CCN1 coordinates neovascularization and stroma deposition in melanoma metastasis	Leask, Andrew	Canada
P034	Deep Proteomics of Non-Muscle Invasive and Muscle Invasive Bladder Cancer Highlights Subgroups With Metabolic, Matrisomal, and Immune Hallmarks And Emphasizes Importance of the Stromal Compartment	Schilling, Oliver	Germany
P035	Tenascin-C orchestrates an immuno-suppressive tumor microenvironment in oral cavity cancer impacting radiotherapy	Loustau, Thomas	France
P036	Extracellular Matrix Profiles are Prognostic in Squamous Non-Small Cell Lung Carcinoma	Parker, Amelia	Australia
P037	ECM regulation of liver metastasis	Castro, Joana	Denmark
P038	Cell-Derived Matrices for Mimicking Breast Cancer Microenvironment	Bagci, Gulsun	Spain
P039	Nutritional effects on adipose tissue and adipocytes ECM throughout the formation of Advanced Glycation End-products (AGEs)	Izgilov, Roza	Israel
P040	Ex vivo modelling of cardiac injury identifies ferroptosis as a potential therapeutic avenue for translational medicine	Fiedler, Jan	Germany
P041	Lab-Grown 3D Human ECM-induced Recovery of Cardiac Function and Associated Changes in Contractile and Metabolic Proteome in Ischemic Myocardium	Broadwin, Mark	United States
P042	Hypoxia drives the progression of a pro-atherogenic arterial extracellular matrix that may be attenuated by heparin	Chuang, Christine	Denmark
P043	Phenotypic and functional characterization of human endothelial progenitor cells in decellularized mouse lung scaffolds in pulmonary hypertension	Feichtenschlager, Vivian	Germany
P044	Anti-GBM serum effects on kidney function and glomerulosclerosis in mice	Frias Hernandez, Alex	Denmark
P045	Multimodal experimental in vivo study on micro-distribution and retention of gadolinium in myocardium in uremic cardiomyopathy	Zang, Yalei	Germany
P046	In vitro studies on the influence of phosphate and gadolinium on vascular GAG expression	Zang, Yalei	Germany
P047	The role of colchicine on cardiac fibrosis in a porcine model of atrial fibrillation	Saljic, Arnela	Denmark
P048	Human C-peptide is a ligand of the elastin-receptor-complex and therewith central to human vascular remodelling and disease in metabolic syndrome	Wensvoort, Gert	Netherlands
P049	The impact of GABA-A positive allosteric modulators as novel first-in-class approach for MASH therapy	Rohbeck, Elisabeth	Germany

P050	Unraveling the Role of Lipid Signaling in Skeletal Muscle Fibrosis: Lysophosphatidic Acid (LPA) Modulates YAP/TAZ Activation in Denervation	Brandan, Enrique	Chile
P051	Pulsed treatment with narmafotinib reduces fibrosis and enhances gemcitabine/Abraxane & FOLFIRINOX response in pancreatic cancer	Murphy, Kendelle	Australia
P052	Semaglutide exerts anti-tumor action in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC	Nøhr-Meldgaard, Jacob	Denmark
P053	Comparison of four methods for dandelion (Taraxacum officinalis) extraction	Kurmanbayeva, Indira	Kazakhstan
P054	Histological disease progression and ALK5i therapeutic efficacy in a chronic DSS- induced mouse model of IBD with intestinal fibrosis	Zachariassen, Line	Denmark
P055	Drug Repurposing Strategy for the Treatment of Cardiac Fibrosis	Jordan, Maria	Germany
P056	Modulation of extracellular matrix markers in human intestinal tissue slices from IBD and non-IBD patients ex vivo	Beneke, Valerie	Germany
P057	A syngenic and orthotopic HCC mouse model to demonstrate high efficacy of combination therapies that modulate the ECM and immune microenvironment	Eichler, Emma	Germany
P058	The K+ Channel KCa3.1 as a Novel Target for Aortic Stenosis	Whitfield, Molly	United Kingdom
P059	Sigma-1 receptor agonist mitigates bleomycin-induced pulmonary fibrosis in mice	Hosszu, Adam	Hungary
P060	Reproducible lung protective effects of a TGFβR1/ALK5 inhibitor in the bleomycin-induced and spirometry-confirmed mouse model of IPF	Korntner, Stefanie H	Denmark
P061	The EMMINENCE phase IIb trial: PRO-C3 and PRO-C6 reveal the anti-fibrotic and pro-metabolic effects of MSDC-0601K in MASH	Guiliani, Alejandro	Denmark
P062	Targeting collagen XVIII-derived endostatin in idiopathic pulmonary arterial hypertension.	Berg, Johannes Lorenz	Austria
P063	Targeting extracellular collagen fibrillogenesis to limit excessive posttraumatic scarring of musculoskeletal tissues	Fertala, Andrzej	United States
P064	Novel ex-vivo model based on patient biopsies to study drugs against the fibrotic microenvironment in lung cancer: Derazantinib as proof-of-concept	Alcaraz, Jordi	Spain
P065	An Updated Review on The Central Mechanism of Action of Paracetamol (acetaminophen): Experimental Evidence and Potential Clinical impact	Pegahi, Rassa	France
P066	Treprostinil reduces clinically relevant fibrosis biomarkers in a Scar-in-a-Jar pulmonary fibrosis model utilizing a fibrotic cocktail	Skarsfeldt, Mark	Denmark
P067	Efficacy assessment of SYN321 injectable therapeutic formulation within an advanced mechanically active osteoarthritis-on-chip model	Piazza, Stefano	Italy

P068	Targeting brain ECM in neurological diseases	Dityatev, Alexander	Germany
P069	Dual epithelial and stromal targeting in breast cancer using a ROCK2-specific inhibitor	Herrmann, David	Australia
P070	Effect of Lisinopril on glomerular and tubular injury in a surgical rat model of progressive chronic kidney disease and kidney failure	Ougaard, Maria	Denmark
P071	Evaluation of TNF-alpha and TNF-beta inhibition and identification of lead pathways to block type I collagen synthesis in Dupuytren's fibrosis	Canty-Laird, Elizabeth	United Kingdom
P072	Collagen type-I mRNA translation inhibitor reduces fibrotic phenotype	Bihari, Ofer	Israel
P073	PDGFR-Inhibitor rescues thrombin induced EMT in retinal pigment epithelium	Ebner, Lynn	Switzerland
P074	Discovery of a Cynomolgus Monkey-Cross-Reactive Anti-Human CD3 mAb for T Cell Engagers	Wang, Michelle	United Kingdom
P075	Modulation of the tumor extracellular matrix and immune cell response by PAK4	Costa, Tânia	Sweden
P076	Targeting Tenascin-C in Cancer	Orend, Gertraud	France
P077	Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	B. Hansen, Henrik	Denmark
P078	Biglycan - A mediator in Pulmonary Arterial Hypertension	Radic, Nemanja	Austria
P079	A gelatinase in liver fibrosis	Gorrell, Mark	Australia
P080	Up-regulation of hyaluronan synthase 2 in hepatocytes contributes to the oxaliplatin-induced portal hypertension	Wu, Ling	China
P081	Collagen degradation but not collagen formation is elevated in Hypersensitivity Pneumonitis	Christoforidou, Georgia	Denmark
P082	Type III and VI collagen fragments in human lung tissue: Differential localization patterns and implications in idiopathic pulmonary fibrosis	Breisnes, Helene Wallem	Denmark
P083	Investigating the role of PKN2 in idiopathic pulmonary fibrosis	McMullan, Catherine	United Kingdom
P084	Comparative Analysis of Core-Matrisome Profiles in Healthy and COPD Lungs	El-Merhie, Natalia	Germany
P085	A single cell atlas of frozen shoulder capsule identifies features associated with inflammatory fibrosis resolution	Dakin, Stephanie	United Kingdom
P086	From Waste to Nutrient: Ammonia's recycling by fibroblast to sustain collagen production	Guillard, Julien	United States
P087	Evaluation of the biological activity of collagen-derived peptides identified in urine	Devos, Hanne	Greece
P088	Mass spectrometry-driven analysis of the extracellular matrix proteome of mouse kidney: advantages and costraints of decellularization	Frattini, Teresa	France
P089	The dark side of procollagen C-proteinase enhancer-2 (PCPE-2): inhibition of bone morphogenetic protein-1/tolloid-like proteinases	Vadon-Le Goff, Sandrine	France

P090	Urinary peptides reflect sex-biased differences in ECM degradation	Mina, Ioanna	Germany
P091	Dynamic pathway modeling of TGFβ and GAS6/AXL induced hepatic stellate cell activation in cirrhosis and liver cancer	Holstein, Elisa	Germany
P092	New synthesis of homotrimeric collagen (I), matrix metalloproteinase-3 and TIMP2 in fibrotic Dupuytren's tissue	Canty-Laird, Elizabeth	United Kingdom
P093	Lost in translation: targeting the post-translational environment	Tyler, Elly	United Kingdom
P094	Proteomic Landscape of ECM and Synovial Tissue in Rheumatoid Arthritis - Methodology and Determinants of Synovial Histological Pathotypes	Stensballe, Allan	Denmark
P095	Longitudinal repair after specific epithelial lung injury reveals distinct gene patterns of the matrisome in the epithelial compartment	Geillinger-Kästle, Kerstin	Germany
P096	Unraveling the post-radiotherapy matrisome dynamics to understand and target glioblastoma recurrence	Manou, Dimitra	Sweden
P097	Cochlin-derived LCCL domain promotes anti-bacterial response through activation of EGFR pathway in epidermal keratinocytes.	Bao, Xinyi	Germany
P098	Exploring the intricacies of hepatic architecture through advanced 3D Liver-on-Chip models	Ferrari, Erika	Italy
P099	Biomanufacturing an in vitro model of dermal burn wound for mechanistic studies and therapeutic screening	Bebiano, Luís	Portugal
P100	Modeling the Aging Bone Marrow Extracellular Matrix: Insights into Skeletal MSC Regulation and Niche Engineering	Marinkovic, Milos	United States
P101	The role of fibroblast specific NLRP3 inflammasome activation on collagen production	Niskala, Alisha	Denmark
P102	Novel tetra-peptide matrikines modulate cholesterol and circadian clock pathways in human skin epithelial cells.	El-Houni, Zeyad	United Kingdom
P103	Aberrant secretion of collagen fragments by tumor-associated fibroblasts in non-small cell lung cancer	Batto, Victoria	Spain
P104	Collagen V Promotes Fibroblast Adhesion and Traction by Enhancing Rigidity of Collagen Network	Han, Sangyoon	United States
P105	A novel culprit in glucose hypometabolism and ECM dysregulation in the context of Alzheimer's disease.	Munter, Lisa	Canada
P106	Imaging the extracellular matrix in live tissues and organisms with a glycan-binding fluorophore	Fiore, Antonio	United States
P107	Full-length laminins are crucial for recreating the cellular niche in vitro	Fereydouni, Noah	Sweden
P108	The Effect of Low-Intensity Pulsed Ultrasound on Extracellular Matrix and its cross linking and organisation.	Almukhlifi, Yazeed	United Kingdom

P109	Utilizing a Clinostat-Based System to Advance in Vitro Liver Fibrosis Modeling and Therapeutic Investigations	Mikkelsen, Karoline	Denmark
P110	Repetitive intratracheal bleomycin induces persistent progressive lung fibrosis in a spirometry-confirmed mouse model of IPF	Graver Petersen, Asbjørn	Denmark
P111	In vitro modelling of systemic sclerosis for drug discovery purposes	Stavenuiter, Fabian	Netherlands
P112	Creation of a Collagen Producing Cell Atlas in a Model of Sub-Retinal Fibrosis	Doyle, Sarah	Ireland
P113	Modeling a micro-niche with tuneable hydrogels for the characterization of fibroblast phenotypes in idiopathic pulmonary fibrosis	Cortès, Birgit	Germany
P114	Stretching the Limits: A Novel Cell Culture Chip to Dissect Pulmonary Fibrosis Mechanisms	Sanz-Fraile, Hector	Spain
P115	High-content imaging assays enable the study of the fibrotic processes, fibroblast-to-myofibroblast transtion and epithelial-to-mesenchymal transition	Leslie, Fiona	United Kingdom
P116	3DPROFIB: a translational in vitro model of extracellular matrix remodeling to test antifibrotic compounds.	Genovese, Federica	Denmark
P117	Bioengineered synthetic hydrogels as dermal extracellular matrix-mimics and their biological function in 3D bioprinted fibroblasts	Pereira, Rúben	Portugal
P118	Exploring Activated Macrophage-Induced Fibrogenesis in Gastrointestinal and Dermal Scar-in-a-Jar Models: Serological Assessment of ECM Remodeling	Pehrsson, Martin	Denmark
P119	Prolonged inflammatory TNF-α stimulation of fibroblasts promotes the formation of type III collagen and fibronectin in response to TGF-β1	Gillesberg, Frederik Søhom	Denmark
P120	Human Precision-Cut Liver Slices to study preclinical assessment of anti-fibrotic drugs	Juli, Cara	Germany
P121	Quantitative histological assessment of atrial fibrillation-associated fibrosis in animal models: a systematic review	Knudsen, Rikke	Denmark
P122	A chronic angiotensin II infusion mouse model of hypertension-induced cardiac fibrosis	Thisted, Louise	Denmark
P123	Experimental sclerosing cholangitis: paradoxical effects of an anti-fibrotic strategy	Zhang, Yanling	Canada
P124	Alport Disease: Assessing organ function in fibrotic kidney disease	Zhang, Yanling	Canada
P125	Development of a Head and Neck 3D Tumor Tissue Construct as Experimental Platform for Assessing Therapeutic Interventions	Coelho, Nuno	Spain
P126	Kinetic Modifications in Cardiac Remodeling in a rat model of CKD	Boukhaled, Juliana	France
P127	Confocal imaging-based T-cells infiltration functional assay using 3D myo-fibroblasts/cancer co-culture spheroids for drug discovery	Martini, Silvia	United Kingdom

Floor Plan



Exhibitors

3	Gubra
4	MedChemExpress
5	Xylyx Bio
6	Inoviv
7	Optics11 Life
8	3Helix
11	Newcells Biotech
12	Nordic Bioscience
13	BiomimX
15	Ectica Technologies

Sponsor & Exhibitor Directory

3Helix

3Helix strives to empower collagen for diagnosing and treating human fibrotic conditions. Our Collagen Hybridizing Peptides (CHPs) can target and bind to denatured or remodeling collagen based on structural recognition. The triple-helical structural recognition enables CHPs to detect the entire collagen alpha chains across all collagen types, regardless of species or tissue type.

www.3helix.com

AbbVie

AbbVie develops innovative medicines and therapies so patients can live more fully.

www.abbvie.com

Antaros Medical

Antaros Medical was founded in 2014 by four entrepreneurs with extensive backgrounds in science and drug development as well as a shared commitment to defying convention. Their mission was to utilize innovative imaging to provide critical evidence-based decision support for pharma companies in clinical development phase.

www.antarosmedical.com

AstraZeneca

Sponsored by

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

www.astrazeneca.com

BiomimX

BiomimX S.r.l. is a pioneer in Organ on a Chip (OoC) technology, producing the next generation of clinically relevant in vitro models for pharmaceutical drug discovery and testing. As every tissue in the body is subject motion, BiomimX proprietary uBeat platform integrates microfluidics, 3D human cell culture and controlled mechanical stimulation to produce "Beating Organs on Chip". These recapitulate, with unprecedented precision and predictability, clinically relevant models reflective of human pathophysiology and complex diseases.

www.biomimx.com

Boehringer Ingelheim

We strive to improve the health of humans and animals - for generations. We work together with integrity and are guided by a shared purpose that defines who we are and what we do.

www.boehringeringelheim.com

Sponsor & Exhibitor Directory

Ectica Technologies

Ectica Technologies was founded in Zurich (Switzerland) in 2015 with the objective to develop innovative tools and technologies for pre-clinical drug discovery and bioresearch. Our products make a significant contribution to integrate hydrogel-based cellular assays in the existing industry workflows.

www.ectica-technologies.com

Engitix

Engitix: decoding the ECM to develop novel therapies in fibrosis and solid tumours. Engitix has pioneered a world-leading and best-in-class human ECM-based discovery platform to identify novel therapeutic targets and biomarkers for treating patients with organ fibrosis and solid tumours. The Engitix platform leverages patient-derived, organ- and disease-specific ECM biomaterials. Engitix has now established a portfolio of partnered and proprietary therapeutic programmes that aims to address the high, clinical unmet need for patients with fibrotic diseases and cancers.

www.engitix.com

FibroBiologics

FibroBiologics is a publicly traded biopharmaceutical company (NASDAQ: FBLG) with a portfolio of 150+ U.S. and International issued/pending patents with a focus on developing and commercializing fibroblast cell-based biological cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, psoriasis, diabetes, cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal. FibroBiologics is leading the next generation of medical advancement in fibroblast cell-based therapies.

www.fibrobiologics.com

Gubra

Gubra is a global preclinical CRO and biotech company specialized in metabolic and fibrotic diseases, such as obesity, diabetes, MASH, CKD, DKD, IBD and IPF. We ensure rapid turnaround time and conclusive data, using clinically translational animal models and cutting-edge technologies, including biomarkers, AI-based fibrosis scoring and 3D whole-organ imaging.

www.gubra.dk

Inoviv

Inoviv is an end-to-end LC-MS proteomics company providing quantitative biomarker solutions to biotech, pharma, and academia for all stages of drug development. With decades of experience validating discovery and targeted LC-MS proteomics workflows, our LC-MS assays demonstrate exceptional throughput and specificity fit for FDA/EMA regulatory submission.

www.inoviv.com

Johnson&Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

www.jnj.com

L'Oréal

L'Oréal was born from science, from a vision, created from the idea of a chemist. Since then, science has remained at the heart of our model with our Research & Innovation for over 115 years. Every day, 4,000 scientists in 20 research centers around the world have a single obsession: innovating to provide our brands and consumers with the best of science and create unequalled beauty experiences that meet their infinitely diverse needs and aspirations.

www.loreal.com/en/beauty-science-and-technology

MedChemExpress

MedChemExpress (MCE) is a leading global provider of research chemicals and bioactive compounds, offering a vast portfolio to research institutes, labs, biotech, and pharma worldwide. Our catalog boasts 60,000+ inhibitors, 10,000+ proteins, 6,000+ life science products, and 200+ screening libraries. With a dedicated team, we are committed to delivering efficient and friendly service to meet your unique needs.

www.medchemexpress.com

Mediar Therapeutics

Our mission: Fearlessly pioneering novel therapies to make meaningful impact and provide hope for patients with fibrotic diseases.

www.mediartx.com

Newcells Biotech

Newcells Biotech provides clients with validated in vitro tools to understand how drugs interact with tissues. We build functional in vitro models of the kidney, retina and lung to improve clinical translation and drug discovery. By applying our expertise in induced pluripotent stem cells (iPSCs), primary tissues, a deep understanding of cellular physiology and organoid technology, we have built validated models and assays that have proven to be predictive of how drugs interact with tissues.

www.newcellsbiotech.co.uk

Sponsor & Exhibitor Directory

Nordic Bioscience	Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. **www.nordicbioscience.com**
Novartis	Our mission is to discover new ways to improve and extend people`s lives. Our vision is to be a trusted leader in changing the practice of medicine. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. **www.novartis.com**
Novo Nordisk	We are a global healthcare company, founded in 1923 and head-quartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. **www.novonordisk.com**
Optics11 Life	Optics11 Life is a life science instrumentation company that offers unique tools for advancements in drug development, regenerative medicine, and biomaterial development – at the cell-scale. We focus on providing robust, high-throughput mechanobiology measurements in-situ and in near-physiological conditions, integrated in the biological workflow, providing researchers functional and easy-to-use readouts. In addition, our latest development provides users with a next generation 3D in vitro modeling platform for engineered muscle bundles. **www.optics11life.com**
PharmaNest	PharmaNest is a Digital Lab specialized in the development and validation of new Digital Pathology AI biomarkers for the quantification of Fibrosis and Inflammation. **www.fibronest.com**

Pliant Therapeutics

At Pliant, our commitment is to bring hope to patients with fibrosis through the discovery and development of breakthrough therapies for fibrotic diseases. Our focus is to better understand the molecular drivers of fibrotic diseases and therefore unlock potentially safer and more effective therapies for patients.

www.pliantrx.com

RA Ventures

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools.

www.raventures.com

Roche Diagnostics

Roche Diagnostics is a division of Roche. We develop and integrate diagnostic solutions that address the challenges of today and anticipate the needs of tomorrow. In more than 100 countries, we offer the industry's most comprehensive in vitro diagnostics solutions, covering molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, and laboratory automation and IT, and decision support solutions.

www.roche.com/about/business/diagnostics

Sengenics

Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision-making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, drug response prediction, and development of companion diagnostics.

www.sengenics.com

Takeda

Creating better health for people and a brighter future for the world is our purpose. The science and technology we advance are constantly evolving. But through our enduring values, our ambition remains steadfast. We strive to deliver truly transformative treatments, contributing significant value to society while creating an exceptional experience for our people.

www.takeda.com

Xylyx Bio

Systemic interactions are fundamental to human biology, from drug discovery to tissue regeneration. Through expert integration of systemic physiology, Xylyx Bio develops and translates cutting-edge regenerative biotechnologies into first-in-class products and services with real-world impact.

www.xylyxbio.com


CAFE OG RESTAURANT
OFELIA
ALLER
FØRSTE
AKT
OFELIA

Media Partners

American Society for Matrix Biology

The mission of the ASMB is to promote basic, translational, and clinical research on the extracellular matrix (ECM), cell-ECM interactions, and ECM-based therapies and devices, and to support the growth and professional development of the ECM research community. The ASMB will accomplish this mission by promoting interactions among academia, scientific societies, industry, and government; facilitating dissemination of relevant knowledge and new findings; providing mentoring opportunities to junior scientists; and advocating sustained funding for research and education.

www.asmb.net

Biochemistry of Collagens, Laminings and Elastin



Biochemistry of Collagens, Laminins, and Elastin: Structure, Function and Biomarkers (Third Edition) provides current data on key structural proteins (collagens, laminins, and elastin), reviews on how these molecules affect pathologies, and information on how selected modifications of these proteins can result in altered signaling properties of the original extracellular matrix (ECM). Further, it discusses the novel concept that an increasing number of components of the extracellular matrix harbor cryptic signaling functions with ties to endocrine function, and how this knowledge may be used to modulate various pathologies, including fibrotic disease.

https://www.sciencedirect.com/book/9780443156175/biochemistry-of-collagens-laminins-and-elastin

British Society for Matrix Biology

The British Society for Matrix Biology (BSMB) brings together scientists from the UK and the rest of the world with an interest in the extracellular matrix and it's associated biology. We wish to provide a forum for the exchange of ideas within our field and help promote the subject to the public at large, furthermore, we aim to help develop and nurture younger scientists with an interest in extracellular matrix biology.

www.bsmb.ac.uk

Danish Society for Matrix Biology

The Danish Society for Matrix Biology (DSMB) is a network for advancing the science of connective tissue, extracellular matrix biology and related subjects. The DSMB arranges seminars, lectures, discussion groups, conferences, symposia, and related networking events for scientists in the field. The DSMB is affiliated with the umbrella society for Danish life science societies, the Danish Biochemical Society.

www.dsmb.dk

Media Partners

Finnish Society for Matrix Biology

The Finnish Society for Matrix Biology aims to promote and support the connective tissue research, as well as the related diseases examination. The association aims to promote cooperation between its members and to convey the latest information on topics of interest to members. The Finnish Society for Matrix Biology is a member of the Federation of Finnish learned societies.

www.sidekudostutkijat.fi

French Society for Matrix Biology

The aim of the Société Française de Biologie de la Matrice Extracellulaire (SFBMEc) is to promote exchanges between researchers, to help scientific and medical research and to contribute to the training of researchers in the field of the extracellular matrix.

www.sfbmec.fr

German Society for Matrix Biology

The German Society for Matrix Biology provides a forum for scientist to promotes the understanding of the extracellular matrix. The main focus of the society is to: suppport research, expand interaction, promote clinical research, conferences, encourage young scientists, and scientific exchange.

www.matrixbiologie.de

International Society for Matrix Biology

The mission of ISMB is to: promote and develop scientific exchanges focused on the study of the ECM between scientists from all spheres and to facilitate the professional development of young scientists, coordinate, sponsor and organize workshops and scientific meetings related to ECM, disseminate information on new techniques, publications and conferences in the field, and recognize excellence in matrix biology research in the form of awards to both junior (Rupert Timpl award) and senior (Distinguished Investigator award) scientists.

www.ismb.org

Matrix Biology Europe 2024

The Matrix Biology Europe (MBE) conference is the main European scientific event for the extracellular matrix research community that takes place every other year in a different European city. From previous records, 400-500 scientists worldwide have participated in MBE meetings. After Florence (Italy) in 2022, it is our great pleasure to organize the 2024 edition in the beautiful and great city of Lyon, France, at the Ecole Normale Supérieure de Lyon, from September 24-27.

https://mbe2024.sciencesconf.org

Matrix Biology Society of Australia and New Zealand

The MBSANZ has a distinguished history of furthering the understanding of and promoting matrix biology research. The extracellular matrix is important in the development, maintenance, pathology and repair of almost every organ in our body. As a society we possess a wealth of knowledge about the extracellular matrix and can connect you with the most appropriate experts for your questions, so get in touch and demystify the matrix.

www.mbsanz.org

STEMCELL Science News

STEMCELL Science News is a complete resource for the latest cell biology news and research, from organoids to immunology. With a curated selection of high-impact publications, reviews, jobs, events, and news, STEMCELL Science News features research updates across a website, Twitter feeds, and 21 weekly email newsletters. Extracellular Matrix News by STEMCELL Science News is a weekly newsletter that summarizes the latest research, news, jobs, and events in extracellular matrix research.

www.stemcellsciencenews.com/extracellular-matrix-news

Notes

Thank you to our sponsors and exhibitors

Gold Sponsors

- Boehringer Ingelheim
- NORDIC BIOSCIENCE
- novo nordisk®
- Roche

Silver Sponsors

- Sponsored by AstraZeneca
- ECTICA TECHNOLOGIES
- gubra
- L'ORÉAL RESEARCH & INNOVATION
- OPTICS11 life
- XYLYX

Symposium Sponsors

- abbvie
- Antaros Medical
- ENGITIX THERAPEUTICS
- fibrobiologics
- Johnson&Johnson
- Mediar Therapeutics
- PHARMANEST DIGITAL PATHOLOGY
- PLIANT
- RAVEN
- sengenics
- Takeda

Exhibitors

- BiomimX THE BEATING ORGANS-ON-CHIP
- ECTICA TECHNOLOGIES
- gubra
- 3HeliX
- inSviv
- MCE® MedChemExpress
- NEWCELLS
- NORDIC BIOSCIENCE
- OPTICS11 life
- XYLYX